Navigation Links
CoLucid Pharmaceuticals Raises $7.5 Million of Planned $9.5 Million
Date:8/30/2011

ne to mild or none 2 hours after dosing (p<0.0001) in 391 patients. Differentiation of individual doses from placebo was seen as early as 30 minutes after dosing. Lasmiditan also achieved secondary endpoints, including relief of nausea, photophobia and phonophobia.  Importantly, because there was no evidence of drug-related cardiovascular effects or chest symptoms in the previous five clinical studies, CoLucid expects the pivotal Phase 3 studies to confirm that lasmiditan's side effect profile is highly differentiated from triptans and ergotamines.

About CoLucid Pharmaceuticals, Inc.

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures. The company's pipeline includes lasmiditan, a novel treatment for migraine headache, COL-204 for wake promotion, and a conjugated stigmine platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. For more information, please visit CoLucid at www.colucid.com.

Media Contact: Kathy Kelly, CoLucid Pharmaceuticals, Inc., 919-806-4304, kkelly@colucid.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE CoLucid Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. CoLucid Appoints Thomas P. Mathers as Chief Executive Officer
2. CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Calif. , May 5, 2015  Desert Valley Medical ... times , is the first U.S. hospital to deploy ... Delivery rooms to help reduce the duration of labor and ... is shortened and the risk of caesarean birth is reduced ... However, most mothers in labor are given epidurals and ...
(Date:5/5/2015)...  IQPC,s 19 th Software Design for Medical ... the Summit Mr. Phani Bidarahalli , GM & Head ... the expert speaker faculty including senior executive from GE Healthcare, ... at The Hotel Kabuki in San Francisco ... on the event website, which can be accessed by visiting ...
(Date:5/5/2015)... -- Big Market Research presents a detailed analysis of ... , ( France , Germany , ... and Japan . Current scientific views on the ... 5-year test volume and sales forecasts by country for HAV NAT, ... Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in the ...
Breaking Medicine Technology:Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 2Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 3Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 4Phani Bidarahalli from Wipro to chair the upcoming 19th Software Design for Medical Devices Summit in San Francisco 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 3
... DIEGO, Jan. 10, 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: ... Linda Amper, Ph.D., as Senior Vice President of Human ... Economics & Outcomes Research (HEOR), and John Womelsdorf, Ph.D., ... will strengthen the management team as the Company prepares ...
... Calif., Jan. 10, 2011 OncoMed Pharmaceuticals, Inc., ... today announced that patient dosing has commenced in a Phase ... tumor cancers.   OMP-59R5 is a monoclonal antibody ... to specifically block these targets to enter human studies.  The ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Key Additions to Management Team 2Optimer Pharmaceuticals Announces Key Additions to Management Team 3Optimer Pharmaceuticals Announces Key Additions to Management Team 4OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 2OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 3
(Date:5/5/2015)... 2015 AxoGen, Inc. (NASDAQ: AXGN), ... $1.6 billion peripheral nerve repair market, reported record revenue ... 31, 2015 compared to $3.14 million in the year-ago ... our proprietary portfolio of nerve repair products - ... Protector – and our solid sales execution delivered another ...
(Date:5/5/2015)... The 2015 Crystal Ball, hosted by the Hepatitis ... outreach and patient advocacy programs. The gala evening included dancing, ... hundreds of supporters. , The 2015 gala was dedicated to ... virus (HBV) by Dr. Baruch S. Blumberg, who passed away ... for his discovery of the virus in 1976. He and ...
(Date:5/5/2015)... 05, 2015 Baptist Medical Center Jacksonville’s ... Cancer (CoC) of the American College of Surgeons. , ... meet more than 30 Commission on Cancer quality care ... process, and maintain levels of excellence in the delivery ... choose to seek care locally at a CoC-accredited cancer ...
(Date:5/5/2015)... " QuickPick Travel ” was featured on NewsWatch as ... small, medium, and large businesses making an impact in their ... expert, conducted the business review and shared with viewers how ... weeks of vacation for free. , Vacations are a sought-after ... world. And when people are preparing for vacations, they’re used ...
(Date:5/5/2015)... NY (PRWEB) May 05, 2015 ProTexting, ... that enables businesses to deploy Mobile Engagement Campaigns and ... Contact . ProTexting clients can now leverage the power ... by collecting and syncing subscribers’ e-mail addresses into the ... “We have recognized that the growing trend of multi-channel ...
Breaking Medicine News(10 mins):Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 2Health News:Hepatitis B Foundation Marks 50th Anniversary of HBV Discovery at its Crystal Ball Gala 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 4Health News:A Platform to Plan the Perfect Vacation was Featured on NewsWatch Television 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 3
... The Delhi High Court Wednesday held that the misuse of ... seriously, stressing that their services be availed of only ... and Justice S.N. Agrawal said: "No ambulance of any of ... used by the medical staff for their private use." ...
... E. McGreevy appears to be knocking on a different door. ... for the right reasons. He has been welcomed into ... James E. McGreevy, who was brought up as a Roman ... at St. Bartholomew's Church in New York. He is presently ...
... says she was upset when her pictures appeared in magazine ... all that blew up, I felt terrible. It appeared that ... am thin because that's what I am, and I was ... Nothing else," people.com quotes her as saying to a magazine. ...
... official of the United Arab Emirates (UAE) said the government ... part of the country's prevention programme of genetic disorders. ... the mother or child's health. But the choice to have ... we decide has to be within the religious and social ...
... that the malfunction of a gene causes schizophrenia and ... of the journal Neuron. ,The researchers said their ... developing treatments for schizophrenia and depression, which have been ... ,In their experiments, the researchers sought to ...
... who have migraine headaches are more than twice as likely ... than soldiers who do not have migraines, according to ... who were given a health screening questionnaire within 90 days ... A total of 2,167 of the soldiers, or 60 percent, ...
Cached Medicine News:Health News:Malfunction of Gene Causes Schizophrenia, Depression 2Health News:Migraines may Be a Symptom of Other Problems for Iraq Soldiers 2
Full plate covers seal all 24 MicroAmp tubes...
An alternative sealing method for samples that are stored in 96-well plates after PCR. The mat is fully autoclavable and can be reused up to 50 times....
Inquire...
Pkg qty: box of 2 bags pack of 25 (Pack = Zippered Bag)...
Medicine Products: